1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses. (September 2015) - Jung, K.H.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Azim, H.A.; Pivot, X.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Gligorov, J.